All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Farnesyltransferase inhibitors

Farnesyltransferase inhibitors

Many proteins involved in signalling pathways undergo farnesylation; therefore inhibiting farnesyltransferase as a targeted therapy against oncogenic Ras is being explored. Farnesyltransferase inhibitor monotherapy with agents such as tipifarnib have been investigated.


All Interventions